6 / 7
Page 31
Notes:
December 03-04, 2018 | Chicago, USA
American Pathology and Oncology Research
&
15
th
International Congress on
Microbial Genetics and Molecular Microbiology
International Conference on
Journal of Clinical & Experimental Pathology | ISSN: 2161-0681 | Volume 8
Basic principles and emerging concepts in Epstein-Barr virus-positive marginal zone lymphoma
E
pstein-Barr virus (EBV) is well known to be associated with various types of B cell, T cell, and NK cell lymphomas. The roles
of EBV in lymphomagenesis are now better elucidated through decades of research. Marginal zone lymphomas (MZL) are a
heterogeneous group of small B-cell lymphomas and traditionally EBV negative. However, recent studies have identified EBV-
positive extranodal MZLs particularly in transplant recipients and at least partially responsive to reduced immunosuppression,
suggesting that these should be regarded as a form of post-transplant lymphoproliferative disorders (PTLD). We expanded the
spectrum of EBV+ MZLs by identifying the first case of nodal MZL, and more cases of extranodal MZL but in non-transplant
settings that included iatrogenic immunosuppression, congenital immune deficiency, and increased age as the only potential
cause of immune dysfunction. These cases were either EBV latency I or II, with a typical plasmacytoid and/or monocytoid B cells
positive for EBV in all cases. Unlike published series that were predominantly IgA-positive, our cases were either positive for IgG
or IgM. Cases arising from cutaneous sites and salivary glands demonstrated differing characteristic features in morphology.
Our data show that EBV+ MZLs can arise in a variety of clinical settings and are most often extranodal. Most patients had a
clinically indolent disease with response to reduction of immune suppression, or immunochemotherapy. As these lymphomas
warrant different management strategies compared to EBV-negative cases, a high suspicion must be kept, and relevant workup
should be performed for nodal and extranodal MZLs in post-transplant and non-transplant but immunocompromised patients.
Biography
Shunyou Gong is the director of Hematology and Hematopathology at the Ann & Robert H Lurie Children’s Hospital of Chicago and assistant professor at
Northwestern University Feinberg School of Medicine. His clinical interests and areas of expertise include pediatric hematopoietic malignancies, inherited bone
marrow failure syndromes, and bleeding or thrombotic disorders. As first-author or corresponding author, he has published many landmark papers on prestigious
journals including Cell, Blood, and American Journal of Surgical Pathology.
shunyou.gong@northwestern.eduShunyou Gong, J Clin Exp Pathol 2018, Volume 8
DOI: 10.4172/2161-0681-C5-056
Shunyou Gong
Northwestern University Feinberg School of Medicine, USA